

Title (en)

COMPOSITION AND METHOD FOR TREATMENT AND PROPHYLAXIS OF INTESTINAL INFECTION AND INFLAMMATION

Title (de)

ZUSAMMENSETZUNG UND VERFAHREN ZUR BEHANDLUNG UND PROPHYLAXE VON DARMINFEKTION UND -ENTZÜNDUNG

Title (fr)

COMPOSITION ET PROCÉDÉ POUR LE TRAITEMENT ET LA PROPHYLAXIE D'INFECTION ET D'INFLAMMATION INTESTINALE

Publication

EP 3341001 A4 20190703 (EN)

Application

EP 16839703 A 20160823

Priority

- SE 1551099 A 20150825
- SE 2016050787 W 20160823

Abstract (en)

[origin: WO2017034460A1] The present invention relates to a composition for use in the treatment and/or prevention of a gastrointestinal condition, comprising at least one Lactobacillus strain, wherein the Lactobacillus strain is chosen from the group consisting of one L. salivarius strain, three L. plantarum strains and one L. brevis strain, wherein the L. salivarius strain is L. salivarius CW30 (LMG P-28887), wherein the L. plantarum strains are L. plantarum Y1An734 (LMG P-28886), L. plantarum SH1313 (LMG P-28884), and L. plantarum KS1 1 (LMG P-28885), and wherein the L. brevis strain is L. brevis SH1 1 1 (LMG P-28888). The present invention also relates to an enema comprising a composition according to the present invention. The present invention also relates to an isolated strain chosen from the group L. salivarius CW30 (LMG P-28887), L. plantarum Y1An734 (LMG P-28886), L. plantarum SH1313 (LMG P-28884), L. plantarum KS11 (LMG P-28885) and L. brevis SH111 (LMG P-28888). The present invention also relates to an isolated strain of L. salivarius CW30 (LMG P-28887) for use in the treatment and/or prevention of an infection by Clostridium difficile NAP/027.

IPC 8 full level

A61K 35/747 (2015.01); **A61P 1/00** (2006.01); **C12N 1/20** (2006.01); **C12R 1/225** (2006.01); **C12R 1/24** (2006.01); **C12R 1/25** (2006.01)

CPC (source: EP KR RU US)

A61K 35/747 (2013.01 - EP KR RU US); **A61P 1/00** (2018.01 - EP RU US); **A61P 1/04** (2018.01 - KR); **A61P 29/00** (2018.01 - KR); **A61P 31/04** (2018.01 - EP US); **C12N 1/20** (2013.01 - EP KR RU US); **C12N 1/205** (2021.05 - EP RU US); **C12R 2001/225** (2021.05 - EP KR RU US); **C12R 2001/24** (2021.05 - EP KR RU US); **C12R 2001/25** (2021.05 - EP KR RU US); **Y02A 50/30** (2018.01 - EP US)

Citation (search report)

[I] SCHOSTER A ET AL: "In vitro inhibition of Clostridium difficile and Clostridium perfringens by commercial probiotic strains", ANAEROBE., vol. 20, 1 April 2013 (2013-04-01), pages 36 - 41, XP002776546, DOI: 10.1016/J.ANAEROBE.2013.02.006

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2017034460 A1 20170302; AU 2016312870 A1 20180308; AU 2016312870 B2 20230420; AU 2023201997 A1 20230504; BR 112018003123 A2 20180925; BR 112018003123 B1 20210928; CA 2995071 A1 20170302; CN 108135948 A 20180608; CN 108135948 B 20220412; DK 3341001 T3 20220321; EP 3341001 A1 20180704; EP 3341001 A4 20190703; EP 3341001 B1 20211229; ES 2909430 T3 20220506; IL 257568 A 20180430; JP 2018526370 A 20180913; JP 6957452 B2 20211102; KR 102656709 B1 20240409; KR 20180041144 A 20180423; MX 2018002093 A 20180912; PL 3341001 T3 20220704; RU 2018105964 A 20190926; RU 2018105964 A3 20200128; RU 2738803 C2 20201217; US 10632159 B2 20200428; US 2018243353 A1 20180830; ZA 201801266 B 20190626

DOCDB simple family (application)

SE 2016050787 W 20160823; AU 2016312870 A 20160823; AU 2023201997 A 20230331; BR 112018003123 A 20160823; CA 2995071 A 20160823; CN 201680049055 A 20160823; DK 16839703 T 20160823; EP 16839703 A 20160823; ES 16839703 T 20160823; IL 25756818 A 20180216; JP 2018510510 A 20160823; KR 20187005513 A 20160823; MX 2018002093 A 20160823; PL 16839703 T 20160823; RU 2018105964 A 20160823; US 201615753692 A 20160823; ZA 201801266 A 20180223